对于体重指数≥27 kg/m2、患有心血管疾病但未患糖尿病的成年人，无论基线 HbA1c 水平如何，semaglutide 都能降低 MACE。

IF 19.6 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of Internal Medicine Pub Date : 2024-11-05 DOI:10.7326/ANNALS-24-02457-JC

Doreen Zhu, William G Herrington

引用次数: 0

摘要

来源引用：Lingvay I、Deanfield J、Kahn SE 等；SELECT 试验研究者。根据 SELECT 中超重或肥胖但无糖尿病患者的基线 HbA1c 和 HbA1c 变化分析塞马鲁肽和心血管预后。糖尿病护理》。2024;47:1360-1369.38907684.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

In adults with BMI ≥27 kg/m² and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA_1c level.

Source citation: Lingvay I, Deanfield J, Kahn SE, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes by baseline HbA_1c and change in HbA_1c in people with overweight or obesity but without diabetes in SELECT. Diabetes Care. 2024;47:1360-1369. 38907684.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Internal Medicine 医学-医学：内科

CiteScore

23.90

自引率

1.80%

发文量

1136

审稿时长

3-8 weeks

期刊介绍： Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.